143 related articles for article (PubMed ID: 30797270)
1. Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients.
Ramachandran G; Hemanth Kumar AK; Kannan T; Sridhar R; Guha SK; Kadam D; Poorana Gangadevi N; Rajapandian T
Indian J Tuberc; 2019 Jan; 66(1):129-133. PubMed ID: 30797270
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients in India.
Ramachandran G; Bhavani PK; Hemanth Kumar AK; Srinivasan R; Raja K; Sudha V; Venkatesh S; Chandrasekaran C; Swaminathan S
Int J Tuberc Lung Dis; 2013 Dec; 17(12):1564-8. PubMed ID: 24200269
[TBL] [Abstract][Full Text] [Related]
3. Improved tuberculosis outcomes with daily vs. intermittent rifabutin in HIV-TB coinfected patients in India.
Jenks JD; Kumarasamy N; Ezhilarasi C; Poongulali S; Ambrose P; Yepthomi T; Devaraj C; Benson CA
Int J Tuberc Lung Dis; 2016 Sep; 20(9):1181-4. PubMed ID: 27510243
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients.
Kouanda S; Ouedraogo HG; Cisse K; Compaoré TR; Sulis G; Diagbouga S; Roggi A; Tarnagda G; Villani P; Sangare L; Simporé J; Regazzi M; Matteelli A
BMC Infect Dis; 2020 Jun; 20(1):449. PubMed ID: 32590942
[TBL] [Abstract][Full Text] [Related]
5. Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy.
Naiker S; Connolly C; Wiesner L; Kellerman T; Reddy T; Harries A; McIlleron H; Lienhardt C; Pym A
BMC Pharmacol Toxicol; 2014 Nov; 15():61. PubMed ID: 25406657
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.
Boulanger C; Hollender E; Farrell K; Stambaugh JJ; Maasen D; Ashkin D; Symes S; Espinoza LA; Rivero RO; Graham JJ; Peloquin CA
Clin Infect Dis; 2009 Nov; 49(9):1305-11. PubMed ID: 19807276
[TBL] [Abstract][Full Text] [Related]
7. Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.
Zhang J; Zhu L; Stonier M; Coumbis J; Xu X; Wu Y; Arikan D; Farajallah A; Bertz R
J Antimicrob Chemother; 2011 Sep; 66(9):2075-82. PubMed ID: 21712242
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis-HIV co-infected African adult patients also receiving rifabutin 150 or 300 mg three times per week.
Ouedraogo HG; Matteelli A; Sulis G; Compaore TR; Diagbouga S; Tiendrebeogo S; Roggi A; Cisse K; Giorgetti PF; Villani P; Sangare L; Simpore J; Regazzi M; Kouanda S
Ann Clin Microbiol Antimicrob; 2020 Jan; 19(1):3. PubMed ID: 31969147
[TBL] [Abstract][Full Text] [Related]
9. Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection.
Kendall MA; Lalloo U; Fletcher CV; Wu X; Podany AT; Cardoso SW; Ive P; Benson CA
Clin Infect Dis; 2021 Aug; 73(4):706-715. PubMed ID: 34398956
[TBL] [Abstract][Full Text] [Related]
10. Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam.
Lan NT; Thu NT; Barrail-Tran A; Duc NH; Lan NN; Laureillard D; Lien TT; Borand L; Quillet C; Connolly C; Lagarde D; Pym A; Lienhardt C; Dung NH; Taburet AM; Harries AD
PLoS One; 2014; 9(1):e84866. PubMed ID: 24465443
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir.
Moultrie H; McIlleron H; Sawry S; Kellermann T; Wiesner L; Kindra G; Gous H; Van Rie A
J Antimicrob Chemother; 2015 Feb; 70(2):543-9. PubMed ID: 25281400
[TBL] [Abstract][Full Text] [Related]
12. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin.
Cato A; Cavanaugh J; Shi H; Hsu A; Leonard J; Granneman R
Clin Pharmacol Ther; 1998 Apr; 63(4):414-21. PubMed ID: 9585795
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of rifabutin among HIV/TB-coinfected children on lopinavir/ritonavir-based ART.
Rawizza HE; Darin KM; Oladokun R; Brown B; Ogunbosi B; David N; Akanmu S; Olaitan O; Chang C; Scarsi KK; Okonkwo P; Kanki PJ
J Antimicrob Chemother; 2019 Sep; 74(9):2707-2715. PubMed ID: 31139825
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients.
Mallolas J; Sarasa M; Nomdedeu M; Soriano A; López-Púa Y; Blanco JL; Martínez E; Gatell JM
HIV Med; 2007 Mar; 8(2):131-4. PubMed ID: 17352770
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs.
Hennig S; Svensson EM; Niebecker R; Fourie PB; Weiner MH; Bonora S; Peloquin CA; Gallicano K; Flexner C; Pym A; Vis P; Olliaro PL; McIlleron H; Karlsson MO
J Antimicrob Chemother; 2016 May; 71(5):1330-40. PubMed ID: 26832753
[TBL] [Abstract][Full Text] [Related]
16. Critical Review: What Dose of Rifabutin Is Recommended With Antiretroviral Therapy?
Yapa HM; Boffito M; Pozniak A
J Acquir Immune Defic Syndr; 2016 Jun; 72(2):138-52. PubMed ID: 26855245
[TBL] [Abstract][Full Text] [Related]
17. Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?
Loeliger A; Suthar AB; Ripin D; Glaziou P; O'Brien M; Renaud-Thery F; Crowley S; Williams B; Ridzon R; Granich R; Gilks C
Int J Tuberc Lung Dis; 2012 Jan; 16(1):6-15. PubMed ID: 21819645
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
Le Tiec C; Barrail A; Goujard C; Taburet AM
Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
[TBL] [Abstract][Full Text] [Related]
19. A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus.
Gallicano K; Khaliq Y; Carignan G; Tseng A; Walmsley S; Cameron DW
Clin Pharmacol Ther; 2001 Aug; 70(2):149-58. PubMed ID: 11503009
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
